Characterization of consumption and costs of antimicrobials in intensive care units in a Brazilian tertiary hospital
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Citação
EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY, v.11, article ID 100289, 5p, 2023
Resumo
Background: The consumption of antimicrobials and the growing resistance of infectious agents to these drugs are not related only to health issues, but also to economic parameters.Objectives: The study objective was to evaluate the consumption of antimicrobials in General and Covid-19 Intensive Care Units (ICUs) and the impact on institutional costs in the largest institute of a tertiary public hospital.Methods: This is a quantitative and retrospective study, which analyzed consumption, through the Defined Daily Dose (DDD), and the annual direct cost of antimicrobials in Reais (R$) and Dollars (US$), from January to December 2021. Results: The total annual consumption (DDD/1000 patient-day) of antimicrobials in the ICUs was 14,368.85. beta-Lactams had the highest total annual value, with a DDD/1000 patient-day of 7062.98, being meropenem the antimi-crobial that reached the highest consumption (3107.20), followed by vancomycin (2322.6). Total consumption was higher in Covid-19 ICUs than in General ICUs, and the annual direct cost of antimicrobials in ICUs was US$560,680.79.Conclusions: The study showed high consumption of broad-spectrum antimicrobials, highlighting the importance of structuring programs to manage the use of antimicrobials, both to reduce antimicrobial consumption and hospital costs, consolidating rational use even in pandemic scenarios.
Palavras-chave
Anti-infective agents, Cost analysis, Critical care
Referências
- Ali M, 2019, INFECT DRUG RESIST, V12, P493, DOI 10.2147/IDR.S187836
- Alshaikh FS, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0272375
- Chiurlo M, 2021, NEW MICROBIOL, V44, P71
- Clancy CJ, 2020, CLIN INFECT DIS, V71, P2736, DOI 10.1093/cid/ciaa524
- Da Costa JNA, 2020, Rev Eletronica Acervo Saude, V44, pe2522
- da Silva LA, 2021, Saude Coletiva, V11, P7274
- Ismail D, 2022, J HOSP INFECT, V124, P47, DOI 10.1016/j.jhin.2022.03.003
- Khamis F, 2020, J INFECT PUBLIC HEAL, V13, P906, DOI 10.1016/j.jiph.2020.06.002
- King LM, 2020, CLIN INFECT DIS, V70, P370, DOI 10.1093/cid/ciz225
- Langford BJ, 2021, CLIN MICROBIOL INFEC, V27, P520, DOI 10.1016/j.cmi.2020.12.018
- Lucien MAB, 2020, Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings
- Mahmud NM, 2022, Rev Bras Farmacia Hosp e Servicos Saude, V13, P1
- Majumder MAA, 2020, INFECT DRUG RESIST, V13, P4713, DOI 10.2147/IDR.S290835
- Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
- Ministerio da Saude, 2019, Plano de acao nacional de prevencao e controle da resistencia aos antimicrobianos no ambito da saude unica
- Mirzaei R, 2020, IUBMB LIFE, V72, P2097, DOI 10.1002/iub.2356
- Pallares CJ, 2017, REV CHIL INFECTOL, V34, P205, DOI 10.4067/S0716-10182017000300001
- Pereira LB, 2021, REV SOC BRAS MED TRO, V54, DOI 10.1590/0037-8682-0861-2020
- Rodríguez-Baño J, 2021, T ROY SOC TROP MED H, V115, P1122, DOI 10.1093/trstmh/trab048
- Seaton RA, 2020, J INFECTION, V81, P952, DOI 10.1016/j.jinf.2020.09.024
- Shankar PR, 2016, ARCH PHARM PRACT, V7, P110, DOI 10.4103/2045-080X.186181
- Tartof SY, 2021, CLIN INFECT DIS, V73, pE4454, DOI 10.1093/cid/ciaa1004
- Versporten A, 2018, LANCET GLOB HEALTH, V6, pE619, DOI [10.1016/s2214-109x(18)30186-4, 10.1016/S2214-109X(18)30186-4]
- Vranjac Alexandre, 2022, CVE-Centro de Vigiωncia Epidemiologica
- Wang YY, 2016, INT J ANTIMICROB AG, V48, P666, DOI 10.1016/j.ijantimicag.2016.09.008
- Wiederhold NP, 2022, CLIN CHEM, V68, P83, DOI 10.1093/clinchem/hvab217
- World Health Organization, ATC/DDD Index 2022
- Xu JH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.832078
- Zhao YZ, 2022, CURR MED SCI, V42, P1106, DOI 10.1007/s11596-022-2598-0